EUCTR2006-001183-24-IT进行中（未招募）不适用
Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD 3
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 390
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed informed consent. Male or female patients aged 18 years or older females of child-bearing potential must have been surgically sterilized or use a reliable method of contraception . Proven diagnosis of IPF according to ATS/ERS statement, of 3 years, with surgical lung biopsy SLB .
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Interstitial lung disease due to conditions other than IPF. Presence of extensive honeycomb HC on Baseline high-resolution computed tomography HRCT scan. The patient is not allowed in BUILD 3 if HC involves more than 5 of the parenchyma in 3 or more of the 6 zones i.e., right and left lung, viewed at the levels of tracheal carina, inferior pulmonary veins, and 1 cm above the dome of the diaphragm , whether the involvement is unilateral or bilateral. Severe concomitant illness limiting life expectancy 1 year . Severe restrictive lung disease forced vital capacity FVC 50 predicted, or FVC 1.2 liter. Diffusing capacity of the lung for carbon monoxide DLCO 30 predicted. Residual volume 120 predicted. Obstructive lung disease forced expiratory volume in 1 second FEV1 /FVC 0.65. Documented sustained improvement of patient s IPF condition up to 12 months prior to randomization with or without IPF-specific therapy. Recent pulmonary or upper respiratory tract infection up to 4 weeks prior to randomization . Acute or chronic impairment other than dyspnea limiting the ability to comply with study requirements e.g., pulmonary function tests . Chronic heart failure with NYHA class III/IV or known left ventricular ejection fraction 25 . ALT/SGPT and/or AST/SGOT 1.5 times the upper limit of the normal ranges ULN . Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C. Serum creatinine 8805; 2.5 mg/dl 221 mmol/l or chronic dialysis. Hemoglobin concentration 75 the lower limit of the normal ranges. Systolic blood pressure 85 mmHg. Pregnancy or breast-feeding. Current drug or alcohol dependence. Chronic treatment with the following drugs prescribed for IPF within 4 weeks of randomization -Oral corticosteroids 20 mg/day of prednisone or equivalent , -Immunosuppressive or cytotoxic drugs, -Antifibrotic drugs including pirfenidone, D-penicillamine, colchicine, TNFa blocker, imatinib, interferon g, cyclophosphamide, azathioprine, -Chronic use of N-acetylcysteine prescribed for IPF . Oral anticoagulants other than those indicated for a venous or arterial thrombotic disease. Treatment with glibenclamide glyburide and calcineurin inhibitors cyclosporine A, tacrolimus up to 1 week prior to randomization. Treatment with an endothelin receptor antagonist up to 3 months prior to randomization. Participation in the BUILD 1 trial. Treatment with another investigational drug up to 3 months prior to randomization or planned treatment. Known hypersensitivity to bosentan or any of the excipients.
研究者
相似试验
进行中（未招募）
1 期
Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3EUCTR2006-001183-24-GBACTELION PHARMACEUTICALS LTD600
进行中（未招募）
不适用
Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3Idiopathic Pulmonary Fibrosis (IPF)MedDRA version: 8.1Level: LLTClassification code 10021240Term: Idiopathic pulmonary fibrosisEUCTR2006-001183-24-DKACTELION PHARMACEUTICALS LTD390
进行中（未招募）
1 期
Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3Idiopathic Pulmonary Fibrosis (IPF)MedDRA version: 8.1Level: LLTClassification code 10021240Term: Idiopathic pulmonary fibrosisEUCTR2006-001183-24-SKACTELION PHARMACEUTICALS LTD390
进行中（未招募）
不适用
Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3EUCTR2006-001183-24-BEACTELION PHARMACEUTICALS LTD460
进行中（未招募）
不适用
Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3Idiopathic Pulmonary Fibrosis (IPF)MedDRA version: 8.1Level: LLTClassification code 10021240Term: Idiopathic pulmonary fibrosisEUCTR2006-001183-24-DEACTELION PHARMACEUTICALS LTD600